Dinutuximab Biosimilar – Anti-ganglioside GD2 mAb – Research Grade

Description of Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb - Research Grade

Dinutuximab Antibody Overview

Dinutuximab is a monoclonal antibody that binds to ganglioside GD2, a tumor-associated antigen highly expressed on neuroblastoma cells and several other cancers. Anti-GD2 antibodies such as Dinutuximab are widely used in research focused on tumor immunology and antibody-mediated immune responses.

This Dinutuximab biosimilar antibody reproduces the target specificity of the reference antibody and is supplied as a research-grade reagent for scientific studies.

Scientists frequently use Dinutuximab antibody to investigate:

• GD2 tumor antigen targeting
• Antibody-dependent cellular cytotoxicity (ADCC)
• Cancer immunotherapy mechanisms
• Neuroblastoma research models

Key Features

Product: Dinutuximab antibody biosimilar
Target: Ganglioside GD2
Antibody type: Monoclonal antibody
Applications: Cancer research and immunotherapy studies
Quality: High purity and consistent production

Dinutuximab Antibody Price

The price of Dinutuximab antibody depends on the requested quantity and formulation.

Custom quantities available upon request !

For detailed information about Dinutuximab antibody price, researchers can request a quote or order directly online.

Buy Dinutuximab Antibody Online

Our Dinutuximab biosimilar antibody is produced to support advanced research programs in oncology and immunotherapy.

Benefits include:

• Reliable biosimilar antibody production
• Competitive Dinutuximab antibody pricing
• Fast international shipping
• Dedicated support for research laboratories

Researchers worldwide trust our antibodies for high-quality and reproducible research results.

SDS-PAGE for Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb

Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.